Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE: RSV Maternal Vaccine in Pregnant Women
NCT04605159Phase 3Terminated
- Sponsor
- GSK
- Start
- Nov 2020
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 24
01
Overview
A Phase 3 trial of RSVPreF3 in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Nov 2020; status: terminated.
02
Drugs
RSVPreF3
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04605159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605159.